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With recent advancements in tissue engineering, several cardiac constructs have been utilized for drug
screening. However, many systems are still not applicable for medium to high throughput workflow commonly
found in drug discovery settings. Adapting techniques from biomaterial and polymer sciences, microfabrication,
and fluid mechanics, we use new biocompatible and biodegradable elastomers to generate particles for
vascularized cardiac tissue engineering applications. We create a novel three-dimensional in vitro model of the
heart by co-culturing endothelial cells, cardiac fibroblasts, and iPSC-derived cardiomyocytes to form
vascularized cardiac spheroids. Using biodegradable UV-curable elastomer poly(octamethylene maleate
(anhydride)) (POMAC) and a droplet microfluidic device, we create a high throughput droplet system by
generating prepolymer particles that are highly controllable and uniformly sized, ranging from 50-200 µm in
diameter. The microfluidic design is optimized for appropriate channel dimensions and flow rates to efficiently
produce large quantities of monodisperse elastomeric particles and crosslink these particles off-chip. Leveraging
the elastic deformation and autofluorescent signals of the POMaC droplets, we can monitor cardiac tissue force
generation and other functional characterization in a non-invasive manner. This engineered 3D cardiac spheroid
will be validated by demonstrating various drug responses, in which the addition of isoproterenol increases the
contractility, whereas treatment of diltiazem produces negative inotropic effects. We will also show that SU5416,
a selective inhibitor of the vascular endothelial growth factor receptor, inhibits vascularization without affecting
cardiac tissue function. We aim to use this model to investigate potential future therapeutic targets for
cardiovascular disease in a high-throughput screening workflow.

